Current management options for recurrent adrenocortical carcinoma

OncoTargets and Therapy

Volumn 6, Issue , 2013, Pages 635-643

  Glover, Anthony R ^a   Ip, Julian C Y ^a   Ting Zhao, Jing ^a   Soon, Patsy S H ^a,d   Robinson, Bruce G ^a,c   Sidhu, Stan B ^a,b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b Endocrine Surgical Unit   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Chemotherapy; Mitotane; Recurrence; Surgery; Treatment

Indexed keywords

ANGIOGENESIS INHIBITOR; BETA CATENIN; BEVACIZUMAB; CAPECITABINE; CISPLATIN; CIXUTUMUMAB; DOXORUBICIN; ERLOTINIB; ETOMIDATE; ETOPOSIDE; EVEROLIMUS; GEMCITABINE; IMATINIB; INTERLEUKIN 13 RECEPTOR ALPHA2; KETOCONAZOLE; MAMMALIAN TARGET OF RAPAMYCIN; METYRAPONE; MICRORNA; MIFEPRISTONE; MITOTANE; STREPTOZOCIN; SUNITINIB; TEMSIROLIMUS; WNT PROTEIN;

ADRENAL CORTEX CARCINOMA; BONE METASTASIS; CANCER DIAGNOSIS; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL EXAMINATION; COMPUTER ASSISTED TOMOGRAPHY; DRUG MEGADOSE; FOLLOW UP; HORMONE SYNTHESIS; HUMAN; LIVER METASTASIS; LUNG METASTASIS; MEDICAL DECISION MAKING; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; RADIOFREQUENCY ABLATION; RECURRENT CANCER; REVIEW; RISK ASSESSMENT; SIGNAL TRANSDUCTION; TREATMENT FAILURE; TREATMENT RESPONSE;

EID: 84879031639     PISSN: 11786930     EISSN: None     Source Type: Journal    
DOI: 10.2147/OTT.S34956     Document Type: Review

References (74)

1. Fassnacht M, Libé R, Kroiss M, Allolio B, Medscape. Adrenocortical carcinoma: a clinician's update. Nat Rev Endocrinol. 2011;7(6):323-335.
2. Wajchenberg BL, Albergaria Pereira MA, Medonca BB, etal. Adrenocortical Carcinoma: clinical and laboratory observations. Cancer. 2000;88(4):711-736.
3. Berruti A, Baudin E, Gelderblom H, etal. Adrenal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann of Oncol. 2012;23(Suppl 7):vii131-vii138.
4. Kebebew E, Reiff E, Duh QY, Clark OH, McMillan A. Extent of disease at presentation and outcome for adrenocortical carcinoma: have we made progress? World J Surg. 2006;30(5):872-878.
5. Kirschner LS. The next generation of therapies for adrenocortical cancers. Trends in Endocrinol Metab. 2012;23(7):343-350.
6. Abiven G, Coste J, Groussin L, etal. Clinical and biological features in the prognosis of adrenocortical cancer: poor outcome of cortisol-secreting tumors in a series of 202 consecutive patients. J Clin Endocrinol Metab. 2006;91(7):2650-2655.
7. Schulick RD, Brennan MF. Long-term survival after complete resection and repeat resection in patients with adrenocortical carcinoma. Ann Surg Oncol. 1999;6(8):719-726.
8. Stojadinovic A, Ghossein RA, Hoos A, etal. Adrenocortical carcinoma: clinical, morphologic, and molecular characterization. J Clin Oncol. 2002;20(4):941-950.
9. Fassnacht M, Allolio B. Clinical management of adrenocortical carcinoma. Best Pract Res Clin Endocrinol Metab. 2009;23(2):273-289.
10. Lau SK, Weiss LM. The Weiss system for evaluating adrenocortical neoplasms: 25 years later. Hum Pathol. 2009;40(6):757-768.
11. Aubert S, Wacrenier A, Leroy X, etal. Weiss system revisited: a clinicopathologic and immunohistochemical study of 49 adrenocortical tumors. Am J Surg Pathol. 2002;26(12):1612-1619.
12. Soon PSH, Gill AJ, Benn DE, etal. Microarray gene expression and immunohistochemistry analyses of adrenocortical tumors identify IGF2 and Ki-67 as useful in differentiating carcinomas from adenomas. Endocr Relat Cancer. 2009;16(2):573-583.
13. Schmitt AA, Saremaslani PP, Schmid SS, etal. Rearrangements at the 11p15 locus and overexpression of insulin-like growth factor-II gene in sporadic adrenocortical tumors. J Clin Endocrinol Metab. 1994; 78(6):1444-1453.
14. Morimoto R, Satoh F, Murakami O, etal. Immunohistochemistry of a proliferation marker Ki67/MIB1in adrenocortical carcinomas: Ki67/MIB1 labeling index is a predictor for recurrence of adrenocortical carcinomas. Endocr J. 2008;55(1):49-55. Available at: http://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=18187873&retmode=ref&cmd=prlinks. Accessed January 14, 2013.
15. Gicquel CC, Bertagna XX, Gaston VV, etal. Molecular markers and long-term recurrences in a large cohort of patients with sporadic adrenocortical tumors. Cancer Res. 2001;61(18):6762-6767.
16. Assie G, Giordano TJ, Bertherat J. Gene expresion profiling in adrenocortical neoplasia. Mol Cell Endocrinol. 2012;351(1):111-117. Available at: http://www.sciencedirect.com/science/article/pii/S0303720711006162. Accessed February 14, 2013.
17. Soon PS, Libé R, Benn DE, etal. Loss of heterozygosity of 17p13, with possible involvement of ACADVL and ALOX15B, in the pathogenesis of adrenocortical tumors. Ann Surg. 2008;247(1):157-164.
18. Patterson EE, Holloway AK, Weng J, Fojo T, Kebebew E. MicroRNA profiling of adrenocortical tumors reveals miR-483 as a marker of malignancy. Cancer. 2010;117(8):1630-1639.
19. Rechache NS, Wang Y, Stevenson HS, etal. DNA methylation profiling identifies global methylation differences and markers of adrenocortical tumors. J Clin Endocrinol Metab. 2012;97(6):E1004-E1013.
20. de Reynies A, Assie G, Rickman DS, etal. Gene expression profiling reveals a new classification of adrenocortical tumors and identifies molecular predictors of malignancy and survival. J Clin Oncol. 2009; 27(7):1108-1115.
21. Schteingart DE, Doherty GM, Gauger PG, etal. Management of patients with adrenal cancer: recommendations of an international consensus conference. Endocr Relat Cancer. 2005;12(3):667-680.
22. Terzolo M, Angeli A, Fassnacht M, etal. Adjuvant mitotane treatment for adrenocortical carcinoma. N Engl J Med. 2007;356(23):2372-2380.
23. Fassnacht M, Johanssen S, Fenske W, etal. Improved survival in patients with stage II adrenocortical carcinoma followed up prospectively by specialized centers. J Clin Endocrinol Metab. 2010;95(11):4925-4932.
24. Huang H, Fojo T. Adjuvant mitotane for adrenocortical cancer-a recurring controversy. J Clin Endocrinol Metab. 2008;93(10):3730-3732.
25. Allolio B, Fassnacht M. Adrenocortical carcinoma: clinical update. J Clin Endocrinol Metab. 2006;91(6):2027-2037.
26. Fassnacht M, Allolio B. What is the best approach to an apparently nonmetastatic adrenocortical carcinoma? Clin Endocrinol. 2010;73(5):561-565.
27. University of Turin, Italy. Efficacy of Adjuvant Mitotane Treatment (ADIUVO). In: ClinicalTrials. gov [website on the Internet]. Bethesda, MD: US National Library of Medicine; 2008 [updated 2011]. Available from: http://clinicaltrials.gov/show/NCT00777244. NLM identifier: NCT00777244. Accessed January 10, 2013.
28. Lacroix A. Approach to the patient with adrenocortical carcinoma. J Clin Endocrinol Metab. 2010;95(11):4812-4822.
29. Arlt W, Biehl M, Taylor AE, etal. Urine steroid metabolomics as a biomarker tool for detecting malignancy in adrenal tumors. J Clin Endocrinol Metab. 2011;96(12):3775-3784.
30. Kendrick ML, Lloyd R, Erickson L, etal. Adrenocortical carcinoma: surgical progress or status quo? Arch Surg. 2001;136:543-549.
31. Crucitti F, Bellantone R, Ferrante A, Boscherini M, Crucitti P, Group TAIRS. The Italian registry for Adrenal Cortical Carcinoma: analysis of a multiinstitutional series of 129 patients. The ACC Italian Registry Study Group. Surgery. 1996;119:161-170.
32. Lombardi CP, Raffaelli M, Boniardi M, etal. Adrenocortical carcinoma: effect of hospital volume on patient outcome. Langenbecks Arch Surg. 2011;397(2):201-207.
33. Pommier RF, Brennan MF. An eleven-year experience with adrenocortical carcinoma. Surgery. 1992;112:963-971.
34. Bellantone R, Ferrante A, Boscheriui M, etal. Role of reoperation in recurrence of adrenal cortical carcinoma: Results from 188 cases collected in the Italian National Registry for Adrenal Cortical Carcinoma. Surgery. 1997;122(6):1212-1218.
35. Fassnacht M, Hahner S, Polat B, etal. Efficacy of adjuvant radiotherapy of the tumor bed on local recurrence of adrenocortical carcinoma. J Clin Endocrinol Metab. 2006;91(11):4501-4504.
36. Lombardi CP, Raffaelli M, De Crea C, etal. Open versus endoscopic adrenalectomy in the treatment of localized (stage I/II) adrenocortical carcinoma: results of a multiinstitutional Italian survey. Surgery. 2012;152(6):1158-1164.
37. Brennan MF. Adrenocortical Carcinoma. CA Cancer J Clin. 1987; 37(6):349-365.
38. Datrice NM, Langan RC, Ripley RT, etal. Operative management for recurrent and metastatic adrenocortical carcinoma. J Surg Oncol. 2011;105(7):709-713.
39. Miller BS, Gauger PG, Hammer GD, Doherty GM. Resection of adrenocortical carcinoma is less complete and local recurrence occurs sooner and more often after laparoscopic adrenalectomy than after open adrenalectomy. Surgery. 2012;152(6):1150-1157.
40. Percarpio B, Knowlton AH. Radiation therapy of adrenal cortical carcinoma. Acta Radiol Ther Phys Biol. 1976;15(4):288-292.
41. Lebastchi AH, Kunstman JW, Carling T. Adrenocortical Carcinoma: Current Therapeutic State-Of-The-Art. J Oncol. 2012;2012:1-11.
42. Habra MA, Ejaz S, Feng L, etal. A Retrospective cohort analysis of the efficacy of adjuvant radiotherapy after primary surgical resection in patients with adrenocortical carcinoma. J Clin Endocrinol Metab. 2013;98(1):192-197.
43. Polat B, Fassnacht M, Pfreundner L, etal. Radiotherapy in adrenocortical carcinoma. Cancer. 2009;115(13):2816-2823.
44. Sabolch A, Feng M, Griffith K, Hammer G, Doherty G, Ben-Josef E. Adjuvant and Definitive Radiotherapy for Adrenocortical Carcinoma. Int J Radiat Oncol Biol Phys. 2011;80(5):1477-1484.
45. Milgrom SA, Goodman KA. The role of radiation therapy in the management of adrenal carcinoma and adrenal metastases. J Surg Oncol. 2012;106(5):647-650.
46. Wood BJ, Abraham J, Hvizda JL, Alexander HR, Fojo T. Radiofrequency ablation of adrenal tumors and adrenocortical carcinoma metastases. Cancer. 2003;97(3):554-560.
47. Icard P, Goudet P, Charpenay C, etal. Adrenocortical carcinomas: surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons study group. World J Surg. 2001;25(7):891-897.
48. Chortis V, Taylor AE, Schneider P, etal. Mitotane therapy in adrenocortical cancer induces CYP3A4 and inhibits 5α-reductase, explaining the need for personalized glucocorticoid and androgen replacement. J Clin Endocrinol Metab. 2013;98(1):161-171.
49. Haak HR, Hermans J, van deVelde CJH, etal. Optimal treatment of adrenocortical carcinoma with mitotane: results in a consecutive series of 96 patients. Br J Cancer. 1994;69(5):947-951.
50. Hahner S, Fassnacht M. Mitotanefor adrenocortical carcinoma treatment. Curr Opin Investig Drugs. 2005;6(4):386-394.
51. Kornely E, Schlaghecke R. Complete remissionof metastasized adrenocortical carcinoma under o, p'-DDD. Exp Clin Endocrinol. 1994;102(1):50-53.
52. Ilias I, Alevizaki M, Philippou G, Anastasiou E, Souvatzoglou A. Sustained remissionof metastatic adrenal carcinoma during long follow up. J Endocrinol Invest. 2001;24(7):532-535.
53. Fassnacht M, Terzolo M, Allolio B, etal. Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med. 2012;366(23):2189-2197.
54. Fassnacht M, Kreissl MC, Weismann D, Allolio B. New targets and therapeutic approaches for endocrine malignancies. Pharmacol Ther. 2009;123(1):117-141.
55. Sperone P, Ferrero A, Daffara F, etal. Gemcitabine plus metronomic 5-fluorouracil or capecitabine as a second-/third-line chemotherapy in advanced adrenocortical carcinoma: a multicenter phase II study. Endocr Relat Cancer. 2010;17(2):445-453.
56. Veytsman I, Nieman L, Fojo T. Management of Endocrine Manifestations and the Use of Mitotane As a Chemotherapeutic Agent for Adrenocortical Carcinoma. J Clin Oncol. 2009;27(27):4619-4629.
57. Gaujoux S, Al-Ahmadie H, Allen PJ, etal. Resection of Adrenocortical Carcinoma Liver Metastasis: Is it Justified? Ann Surg Oncol. 2012;19(8):2643-2651.
58. Winkel den JO, Pfannschmidt J, Muley T, etal. Metastatic adrenocortical carcinoma: results of 56 pulmonary metastasectomies in 24 patients. Ann Thorarc Surg. 2011;92(6):1965-1970.
59. Mihai R, Iacobone M, Makay O, etal. Outcome of operation in patients with adrenocortical cancer invading the inferior vena cava-a European Society of Endocrine Surgeons (ESES) survey. Langenbecks Arch Surg. 2011;397(2):225-231.
60. Pacella CM, Stasi R, Bizzarri G, etal. Percutaneous laser ablation of unresectable primary and metastatic adrenocortical carcinoma. Eur J Radiol. 2008;66(1):88-94.
61. Adam P, Hahner S, Hartmann M, etal. Epidermal growth factor receptor in adrenocortical tumors: analysis of gene sequence, protein expression and correlation with clinical outcome. Mod Pathol. 2010;23(12): 1596-1604.
62. Quinkler M, Hahner S, Wortmann S, etal. Treatment of advanced adrenocortical carcinoma with erlotinib plus gemcitabine. J Clin Endocrinol Metab. 2008;93(6):2057-2062.
63. Gross DJ, Munter G, Bitan M, etal. The role of imatinib mesylate (Glivec) for treatment of patients with malignant endocrine tumors positive for c-kit or PDGF-R. Endocr Relat Cancer. 2006;13(2):535-540.
64. Kroiss M, Quinkler M, Johanssen S, etal. Sunitinib in refractory adrenocortical carcinoma: a phase II, single-arm, open-label trial. J Clin Endocrinol Metabolism. 2012;97(10):3495-3503.
65. Tacon LJ, Prichard RS, Soon PS, Robinson BG, Clifton-Bligh RJ, Sidhu SB. Current and Emerging Therapies for AdvancedAdrenocortical Carcinoma. Oncologist. 2011;16(1):36-48.
66. Macaulay VM, Middleton MR, Eckhardt SG, etal. Phase I study of OSI-906, dual tyrosine kinase inhibitor of insulin-like growth factor-1 receptor (IGF-1R) and insulin receptor (IR) in combination with erlotinib (E) in patients with advanced solid tumors. J Clin Oncol. 2010;28(15):3016.
67. Astellas Pharma Inc. A Study of OSI-906 in Patients With Locally Advanced or Metastatic Adrenocortical Carcinoma (GALACCTIC). In: ClinicalTrials. gov [website on the Internet]. Bethesda, MD: US National Library of Medicine; 2009 [updated 2012]. Available from http://clinicaltrials.gov/show/NCT00924989. NLM identifier NCT00924989. Accessed January 10, 2013.
68. Wortmann S, Quinkler M, Ritter C, etal. Bevacizumab plus capecitabine as a salvage therapy in advanced adrenocortical carcinoma. Eur J Endocrinol. 2010;162(2):349-356.
69. Memmott RM, Dennis PA. Akt-dependent and-independent mechanisms of mTOR regulation in cancer. Cell Signal. 2009;21(5):656-664.
70. Fraenkel M, Gueorguiev M, Barak D, Salmon A, Grossman AB, Gross DJ. Everolimus therapy for progressive adrenocortical cancer. Endocrine. Epub February 16, 2013.
71. Naing A, LoRusso P, Fu S, etal. Insulin growth factor receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with metastatic adrenocortical carcinoma. Br J Cancer. 2013;108(4):826-830.
72. Tissier F, Cavard C, Groussin L, etal. Mutations of beta-catenin in adrenocortical tumors: activation of the wnt signaling pathway is a frequent event in both benign and malignant adrenocortical tumors. Cancer Res. 2005;65(17):7622-7627.
73. Iorio MV, Croce CM. MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review. EMBO Mol Med. 2012;4(3):143-159.
74. Jain M, Zhang L, He M, etal. Interleukin-13 receptor alpha2 is a novel therapeutic target for human adrenocortical carcinoma. Cancer. 2012; 118(22):5698-5708.